By Associate Professor Mandy Ballinger

Conference Abstracts

Thavaneswaran S; Ballinger ML; Grady J; Cowley M; Joshua A; Sebastian L; Collignon E; Silvestri A; Kansara M; Pinese M; Sjoquist KM; Hague W; Lee CK; Simes J; Thomas DM, 2019, 'The Cancer Molecular Screening and Therapeutics Program (MoST): Actionable mutation frequencies in a population with rare and less common cancers.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, pp. 3136 - 3136, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.3136

Thavaneswaran S; Sebastian L; Ballinger M; Cowley M; Grady J; Joshua A; Lee C; Sjoquist K; Hague W; Simes J; Thomas D, 2018, 'The cancer molecular screening and therapeutics program (MoST): A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies', in Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii147, http://dx.doi.org/10.1093/annonc/mdy279.434

Jones RM; Melton PE; Rea A; Ingley E; Ballinger ML; Wood DJ; Thomas DM; Moses EK, 2016, 'Whole Exome Sequencing in Multigenerational Mixed Cancer Families Identifies a Putative Risk Variant in the PDIA2 Gene', in GENETIC EPIDEMIOLOGY, WILEY-BLACKWELL, CANADA, Toronto, Vol. 40, pp. 644 - 644, presented at Annual Meeting of the International-Genetic-Epidemiology-Society, CANADA, Toronto, 24 October 2016 - 26 October 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000386034800102&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

McBride KA; Young M-A; Schlub TE; Kirk J; Tattersall MHN; Ballinger M; Thomas D; Mitchell G, 2015, 'THE PSYCHOSOCIAL EFFECTS OF A WHOLE BODY MRI SCREENING TRIAL IN SARCOMA PATIENTS WITH A GERMLINE TP53 MUTATION', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, Vol. 11, pp. 178 - 178, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800325&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Peng G; Bojadzieva J; Ballinger ML; Thomas DM; Strong L; Wang W, 2015, 'LFSpro: A risk assessment tool to estimate TP53 mutation status in families with Li-Fraumeni syndrome', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-2762

Preprints

Tran M; Chan JC; Huang ML; Kansara M; Grady JP; Napier CE; Thavaneswaran S; Ballinger ML; Thomas DM; Lin FP, 2025, A Robust BERT-Based Deep Learning Model for Automated Cancer Type Extraction from Unstructured Pathology Reports, http://dx.doi.org/10.48550/arxiv.2508.15149

Shin SJ; Dodd E; Peng G; Bojadzieva J; Chen J; Amos C; Mai P; Savage S; Ballinger M; Thomas D; Yuan Y; Strong L; Wang W, 2019, Risk of differential cancer types over age in families with Li-Fraumeni syndrome: a validation study using multi-center cohorts, http://dx.doi.org/10.1101/567727

Thavaneswaran S; Lin FP; Kansara M; Grady JP; Espinoza D; Joshua AM; Grimison P; Craft P; Cosman R; Lee C; Harwood K; Chinchen S; Corpuz T; Ballinger M; Sebastian L; Simes J; Thomas D, A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers, http://dx.doi.org/10.1101/2022.06.30.22277092

Thavaneswaran S; Sebastian L; Kansara M; Ballinger M; Espinoza D; Lin F; Lee C; Sjoquist K; Grady J; Cowley M; Joshua A; Qiu M; Oakes S; Simes J; Thomas D, A Signal-seeking Phase Iia Trial of Palbociclib in Advanced Cancers With Cell Cycle Pathway Alterations – A Substudy of the Molecular Screening and Therapeutics (Most) Program, http://dx.doi.org/10.21203/rs.3.rs-254137/v1

Collet L; Telouk P; Albarede F; Girodet M; Maqua C; Rogasik M; Ducimetière F; Tabone-Eglinger S; Brahmi M; Dufresne A; Thomas DM; Ballinger ML; Blay J-Y; Ray-Coquard I, Connecting the changing metallomic spectrum and survival in sarcoma: a pilot study, http://dx.doi.org/10.21203/rs.3.rs-3291225/v1

Lin FP; Thavaneswaran S; Grady JP; Ballinger M; Kansara M; Oakes SR; Desai J; Lee CK; Simes J; Thomas DM, Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology, http://dx.doi.org/10.1101/2020.12.18.20248521

Hersch J; O’Hara L; Butow P; Ballinger M; Laidsaar-Powell R; Bartley N; McCaffery K; Latin A; Cockburn C; Delaney C; Tucker K; Juraskova I, Development of a question prompt list to support Consent for Genomic Testing (CoGenT) and research, http://dx.doi.org/10.21203/rs.3.rs-8674757/v1

Best M; Bartley N; Napier C; Fisher A; Ballinger M; Thomas D; Goldstein D; Tucker K; Biesecker B; Butow P, Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study, http://dx.doi.org/10.21203/rs.3.rs-1190781/v1

Kaur S; Sikta N; Schafferhans A; Bordin N; Cowley MJ; Thomas DM; Ballinger ML; O’Donoghue SI, Streamlined use of protein structures in variant analysis, http://dx.doi.org/10.1101/2021.09.10.459756

Other

Nagrial A; Carlino MS; Gunjur A; Brown MP; Harris S; Underhill C; Zielinski R; Kee D; Lam W-S; Chan H; Harrup R; So J; Collins IM; Michael M; Chionh F; Uy C; Mariadason J; Torres J; Ballinger ML; Grady JP; Tavancheh E; Palmer J; Thomas DM; Wilkie K; Cebon J; Klein O, 2026, Data from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial, http://dx.doi.org/10.1158/1078-0432.c.8630732

Nagrial A; Carlino MS; Gunjur A; Brown MP; Harris S; Underhill C; Zielinski R; Kee D; Lam W-S; Chan H; Harrup R; So J; Collins IM; Michael M; Chionh F; Uy C; Mariadason J; Torres J; Ballinger ML; Grady JP; Tavancheh E; Palmer J; Thomas DM; Wilkie K; Cebon J; Klein O, 2026, Supplementary Table S1 from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial, http://dx.doi.org/10.1158/1078-0432.33143048

Cote GM; Aberoumand M; Choy E; Sebastian L; Mazzola E; Grimison P; Merriam P; Ballinger M; Thavaneswaran S; Lin F; Grady JP; Millward M; Brown MP; Harrup R; Espinoza D; Demetri G; Littlefield BA; Simes RJ; George S; Thomas D, 2026, Data from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma, http://dx.doi.org/10.1158/1078-0432.c.8509442

Cote GM; Aberoumand M; Choy E; Sebastian L; Mazzola E; Grimison P; Merriam P; Ballinger M; Thavaneswaran S; Lin F; Grady JP; Millward M; Brown MP; Harrup R; Espinoza D; Demetri G; Littlefield BA; Simes RJ; George S; Thomas D, 2026, Supplementary Tables 1-3 from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma, http://dx.doi.org/10.1158/1078-0432.32530688

Back to profile page